Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Shares Climb 0.6% – Here’s What Happened

by · The Cerbat Gem

Invesco Pharmaceuticals ETF (NYSEARCA:PJP – Get Free Report) shares were up 0.6% during mid-day trading on Monday. The stock traded as high as $126.80 and last traded at $125.80. Approximately 40,426 shares traded hands during trading, an increase of 12% from the average daily volume of 36,011 shares. The stock had previously closed at $125.03.

Invesco Pharmaceuticals ETF Stock Performance

The company has a market cap of $562.41 million, a PE ratio of 15.59 and a beta of 0.44. The firm has a fifty day simple moving average of $125.84 and a 200 day simple moving average of $114.11.

Hedge Funds Weigh In On Invesco Pharmaceuticals ETF

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lodestone Wealth Management LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter valued at $25,000. Rockefeller Capital Management L.P. increased its holdings in shares of Invesco Pharmaceuticals ETF by 20.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,230 shares of the company’s stock worth $129,000 after buying an additional 209 shares during the last quarter. Latitude Advisors LLC purchased a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth $29,000. Geneos Wealth Management Inc. raised its position in shares of Invesco Pharmaceuticals ETF by 24.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,722 shares of the company’s stock worth $179,000 after buying an additional 335 shares during the period. Finally, Fifth Third Bancorp purchased a new position in shares of Invesco Pharmaceuticals ETF in the 1st quarter worth $36,000.

About Invesco Pharmaceuticals ETF

(Get Free Report)

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.

See Also